scRNA-seq can also be used to access specific tumor tissues and tumor cells, thus helping to elucidate the mechanism of drug resistance in patients who are not sensitive to PD-1/PD-L1 and/or CTLA-4 therapy. This evidence concerns the gene CTLA4 and neoplasm.